Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Poolbeg Pharma PLC

POLB.L ✓ COMPLIANT ☆ Track — members

LSE · Healthcare · Biotechnology & Medical Research ·

UK Micro Cap Analyst: STRONG BUY

Last Close

$0.12

▼ -2.30%

Market Cap $87.51M · Vol 1.71M

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$87.51M

Micro Cap

Div Yield

N/A

EPS Growth

+15.82%

YoY

RSI (14)

81.67

Momentum

Beta

1.70

vs Market

52W High

$0.12

5.56% below

52W Low

$0.04

198.83% above

Volume

1.71M

Avg 3.43M

P/B

3.24

Price-to-book

ROE

-63.72%

Return on equity

Free Float

61.09%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Poolbeg Pharma PLC (POLB.L) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does POLB.L pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+2.41%

+40.50%

+73.47%

+80.85%

YTD

+112.50%

+188.14%

+19.12%

-17.07%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-7,672,824.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	-63.72%
ROA · ROIC	-57.20% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	3.24
P/FCF	N/A
EPS Growth	+15.82%
Outstanding Shares	763.44M

Technical Indicators

50-Day SMA	$0.10
200-Day SMA	$0.07
RSI (14)	81.67
Beta	1.70
52-Week High	$0.12
52-Week Low	$0.04

Volume Today	1.71M
Avg Daily Volume (30D)	3.43M
Relative Volume	0.50x
Volatility (10D)	77.74
Volatility (30D)	68.34
Free Float	61.09%

Analyst Consensus

STRONG BUY

Current Price $0.12

Mean Target $0.26

52W Low$0.04 52W High$0.12

Current

Target

$0.04 $0.12

Current Analyst target

+123.30% upside potential · 2 analysts

Identifiers

ExchangeLSE

FIGIBBG011J1D865

ISINGB00BKPG7Z60

CountryUnited Kingdom

Sub-IndustryBio Therapeutic Drugs

Earnings DateSep 28, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -2.85% ARGX.BR argenx SE -3.21% ARGX argenx SE -0.66% INSM Insmed Inc -2.05% 2269.HK WuXi Biologics (Cayman) Inc -1.27%

Company Profile

Poolbeg Pharma plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is focused on the development of medicines to address unmet medical needs. Its clinical programmes target addressable markets, including cancer immunotherapy-induced Cytokine Release Syndrome (CRS) and metabolic conditions, such as obesity with the development of an oral encapsulated glucagon-like peptide (GLP-1R) agonist. Its pipeline includes POLB 001 Oncology, POLB 001 Influenza, AI Programmes and Oral Encapsulated GLP-1programme. POLB 001 is an orally delivered p38 MAP Kinase inhibitor being developed for the prevention of CRS associated with Bispecific Antibodies and CAR T immunotherapy treatments in cancer. It uses artificial intelligence to identify infectious disease drug targets & treatments. The Oral Encapsulated GLP-1 programme leverages an advanced delivery system that encapsulates active pharmaceutical ingredients using Generally Regarded as Safe (GRAS) components.